MedTrace Logo

High Flow Nasal Cannula in Immunocompromised Patient With Acute Respiratory Failure

NCT04293991 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-03-03

No results posted yet for this study

Summary

This study will be conducted in Ain Shams University Hospital in the general intensive care unit after ethical committee approval number (FMASU R 9/2020) .It is a prospective randomized controlled study. Eligible patients will be randomized by computer system to one of two groups either High Flow Nasal Oxygen (HFNO) group or Non Invasive Ventilation (NIV) group. Inclusion criteria includes admitted immunocompromised patients to our general 34 beds ICU with acute hypoxemic respiratory failure (ARF).

Conditions

  • High Flow Nasal Cannula
  • Non Invasive Ventilation
  • Acute Respiratory Failure

Interventions

DEVICE

High Flow Nasal Cannula

Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.

DEVICE

Non Invasive Ventilation

Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sameh Salem, MD · Professor Doctor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-07-31
Completion
2020-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293991 on ClinicalTrials.gov